Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 [GH2], prototype HIV-2 [GH1], and prototype HIV-1 [GH3] to inhibition by ddCyd and ddIno
Identifieur interne : 001378 ( Main/Exploration ); précédent : 001377; suivant : 001379Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 [GH2], prototype HIV-2 [GH1], and prototype HIV-1 [GH3] to inhibition by ddCyd and ddIno
Auteurs : N. K. Ayisi [Ghana]Source :
- East African medical journal [ 0012-835X ] ; 1995.
Descripteurs français
- KwdFr :
- Antiviraux (pharmacologie), Culture virale, Didéoxyinosine (pharmacologie), Effet cytopathogène viral (), Ghana, Humains, Tests de sensibilité microbienne, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (pathogénicité), Zalcitabine (pharmacologie), Évaluation préclinique de médicament.
- MESH :
- pathogénicité : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2).
- pharmacologie : Antiviraux, Didéoxyinosine, Zalcitabine.
- Pascal (Inist)
- Culture virale, Effet cytopathogène viral, Ghana, Humains, SIDA, Tests de sensibilité microbienne, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2), Virus HIV1, Virus HIV2, Pathogénie, Etude comparative, Souche pathogène, Local, In vitro, Prototype, Ghana, Évaluation préclinique de médicament.
- Wicri :
English descriptors
- KwdEn :
- AIDS, Antiviral Agents (pharmacology), Comparative study, Cytopathogenic Effect, Viral (drug effects), Didanosine (pharmacology), Drug Evaluation, Preclinical, Ghana, HIV-1 (classification), HIV-1 (drug effects), HIV-1 (pathogenicity), HIV-1 virus, HIV-2 (classification), HIV-2 (drug effects), HIV-2 (pathogenicity), HIV-2 virus, Humans, In vitro, Microbial Sensitivity Tests, Pathogen strain, Pathogenesis, Premises, Prototype, Virus Cultivation, Zalcitabine (pharmacology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Didanosine, Zalcitabine.
- geographic : Ghana.
- classification : HIV-1, HIV-2.
- drug effects : Cytopathogenic Effect, Viral, HIV-1, HIV-2.
- pathogenicity : HIV-1, HIV-2.
- Drug Evaluation, Preclinical, Humans, Microbial Sensitivity Tests, Virus Cultivation.
Abstract
The cytopathicity and susceptibility of prototype HIV-1 [HTL VIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTL VIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTL VIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000166
- to stream PascalFrancis, to step Curation: 000162
- to stream PascalFrancis, to step Checkpoint: 000155
- to stream Main, to step Merge: 001488
- to stream PubMed, to step Corpus: 000697
- to stream PubMed, to step Curation: 000697
- to stream PubMed, to step Checkpoint: 000697
- to stream Ncbi, to step Merge: 000C47
- to stream Ncbi, to step Curation: 000C47
- to stream Ncbi, to step Checkpoint: 000C47
- to stream Main, to step Merge: 001441
- to stream Main, to step Curation: 001378
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 [GH2], prototype HIV-2 [GH1], and prototype HIV-1 [GH3] to inhibition by ddCyd and ddIno</title><author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N. K." last="Ayisi">N. K. Ayisi</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana</s1><s2>Legon</s2><s3>GHA</s3><sZ>1 aut.</sZ></inist:fA14><country>Ghana</country><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">96-0248609</idno><date when="1995">1995</date><idno type="stanalyst">PASCAL 96-0248609 INIST</idno><idno type="RBID">Pascal:96-0248609</idno><idno type="wicri:Area/PascalFrancis/Corpus">000166</idno><idno type="wicri:Area/PascalFrancis/Curation">000162</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000155</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000155</idno><idno type="wicri:doubleKey">0012-835X:1995:Ayisi N:differential:cytopathicity:and</idno><idno type="wicri:Area/Main/Merge">001488</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8904046</idno><idno type="wicri:Area/PubMed/Corpus">000697</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000697</idno><idno type="wicri:Area/PubMed/Curation">000697</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000697</idno><idno type="wicri:Area/PubMed/Checkpoint">000697</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000697</idno><idno type="wicri:Area/Ncbi/Merge">000C47</idno><idno type="wicri:Area/Ncbi/Curation">000C47</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C47</idno><idno type="wicri:doubleKey">0012-835X:1995:Ayisi N:differential:cytopathicity:and</idno><idno type="wicri:Area/Main/Merge">001441</idno><idno type="wicri:Area/Main/Curation">001378</idno><idno type="wicri:Area/Main/Exploration">001378</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 [GH2], prototype HIV-2 [GH1], and prototype HIV-1 [GH3] to inhibition by ddCyd and ddIno</title><author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N. K." last="Ayisi">N. K. Ayisi</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana</s1><s2>Legon</s2><s3>GHA</s3><sZ>1 aut.</sZ></inist:fA14><country>Ghana</country><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author></analytic><series><title level="j" type="main">East African medical journal</title><title level="j" type="abbreviated">East Afr. med. j.</title><idno type="ISSN">0012-835X</idno><imprint><date when="1995">1995</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">East African medical journal</title><title level="j" type="abbreviated">East Afr. med. j.</title><idno type="ISSN">0012-835X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Antiviral Agents (pharmacology)</term><term>Comparative study</term><term>Cytopathogenic Effect, Viral (drug effects)</term><term>Didanosine (pharmacology)</term><term>Drug Evaluation, Preclinical</term><term>Ghana</term><term>HIV-1 (classification)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (pathogenicity)</term><term>HIV-1 virus</term><term>HIV-2 (classification)</term><term>HIV-2 (drug effects)</term><term>HIV-2 (pathogenicity)</term><term>HIV-2 virus</term><term>Humans</term><term>In vitro</term><term>Microbial Sensitivity Tests</term><term>Pathogen strain</term><term>Pathogenesis</term><term>Premises</term><term>Prototype</term><term>Virus Cultivation</term><term>Zalcitabine (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term><term>Culture virale</term><term>Didéoxyinosine (pharmacologie)</term><term>Effet cytopathogène viral ()</term><term>Ghana</term><term>Humains</term><term>Tests de sensibilité microbienne</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) ()</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (pathogénicité)</term><term>Zalcitabine (pharmacologie)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Didanosine</term><term>Zalcitabine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Didéoxyinosine</term><term>Zalcitabine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Microbial Sensitivity Tests</term><term>Virus Cultivation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Culture virale</term><term>Effet cytopathogène viral</term><term>Ghana</term><term>Humains</term><term>SIDA</term><term>Tests de sensibilité microbienne</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term><term>Virus HIV1</term><term>Virus HIV2</term><term>Pathogénie</term><term>Etude comparative</term><term>Souche pathogène</term><term>Local</term><term>In vitro</term><term>Prototype</term><term>Ghana</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prototype</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The cytopathicity and susceptibility of prototype HIV-1 [HTL VIII<sub>B</sub>] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTL VIII<sub>B</sub>] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTL VII<sub>B</sub>] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</div></front></TEI><affiliations><list><country><li>Ghana</li></country><region><li>Région du Grand Accra</li></region><settlement><li>Accra</li><li>Legon (Ghana)</li></settlement><orgName><li>Université du Ghana</li></orgName></list><tree><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N. K." last="Ayisi">N. K. Ayisi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001378 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001378 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:96-0248609
|texte= Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 [GH2], prototype HIV-2 [GH1], and prototype HIV-1 [GH3] to inhibition by ddCyd and ddIno
}}
| This area was generated with Dilib version V0.6.31. |  |